Soleno Therapeutics has started a Phase III clinical trial of Diazoxide Choline Controlled-Release (DCCR) tablet for the treatment of patients with Prader-Willi Syndrome (PWS).
The randomised, placebo-controlled trial will enrol around 100 PWS patients at 10-15 sites in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Seattle Children’s Hospital in the US is the first site to be activated for the trial, which is expected to be completed over a period of nine to 12 months.
Soleno has appointed Dr Parisa Salehi as the Principal Investigator for the trial at the Seattle Children’s Hospital site.
Salehi said: “Prader-Willi Syndrome leads to hyperphagia that can cause life-threatening obesity if left uncontrolled.
“This excessive hunger can cause significant harm to the lives of these individuals and their families. There is a lack of effective medical therapy targeting hunger in this population, and such a drug would be life-altering.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Based on the data generated to date, DCCR has the potential to address this treatment void.”
DCCR is a new, extended-release, crystalline salt formulation of diazoxide, which is given once-daily to the patients and has been used for ages for treating patients suffering from a few rare diseases in neonates, infants, children and adults.
The tablet, however, has not been approved for use in PWS.
According to Prader-Willi Syndrome Association USA, one in 12,000 to 15,000 people in the US is estimated to have PWS, which leads to hyperphagia, a chronic feeling of insatiable hunger that significantly reduces the quality of life for PWS patients and their families.
